rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
prasugrel mylan
mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - antithrombotic agents - prasugrel mylan, co gis med acetylsalisylsyre (asa), er indikert for forebygging av atherothrombotic hendelser hos voksne pasienter med akutt koronar syndrom (i. ustabil angina, ikke-st-segmentet elevation myocardial infarction [ua/nstemi] eller st-segmentet elevation myocardial infarction [stemi]) gjennomgår primære eller forsinket perkutan koronar intervensjon (pci).
aurorix 300 mg
viatris as - moklobemid - tablett, filmdrasjert - 300 mg
aurorix 150 mg
viatris as - moklobemid - tablett, filmdrasjert - 150 mg
bondil 500 mikrog
viatris as - alprostadil - urethralstift - 500 mikrog
bondil 1000 mikrog
viatris as - alprostadil - urethralstift - 1000 mikrog
dymista 137 mikrog/ dose / 50 mikrog/ dose
viatris as - azelastinhydroklorid / flutikasonpropionat - nesespray, suspensjon - 137 mikrog/ dose / 50 mikrog/ dose
epipen 300 mikrog
viatris as - adrenalin - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 mikrog
epipen jr 150 mikrog
viatris as - adrenalin - injeksjonsvæske, oppløsning i ferdigfylt penn - 150 mikrog